drugset / Trial / NCT00973973

Efficacy and Safety Study of Elagolix in Women With Endometriosis

NCT00973973

Phase 2 Completed 137 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate elagolix (NBI-56418) compared to placebo for its effects on endometriosis related pelvic pain and its safety.

Timeline

Start
2009-10-12
Primary completion
2010-09-22
Completion
2010-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Elagolix Small molecule 150 mg Oral

Indications